Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Profit After Tax (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Profit After Tax for 4 consecutive years, with -$19.2 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 46.85% to -$19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$9.6 million through Dec 2025, up 92.44% year-over-year, with the annual reading at -$9.6 million for FY2025, 92.43% up from the prior year.
  • Profit After Tax for Q4 2025 was -$19.2 million at Century Therapeutics, up from -$34.4 million in the prior quarter.
  • The five-year high for Profit After Tax was $76.6 million in Q1 2025, with the low at -$39.4 million in Q4 2023.
  • Average Profit After Tax over 4 years is -$25.2 million, with a median of -$31.5 million recorded in 2022.
  • The sharpest move saw Profit After Tax fell 24.35% in 2023, then skyrocketed 372.82% in 2025.
  • Over 4 years, Profit After Tax stood at -$31.7 million in 2022, then dropped by 24.35% to -$39.4 million in 2023, then increased by 8.44% to -$36.1 million in 2024, then soared by 46.85% to -$19.2 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$19.2 million, -$34.4 million, and -$32.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.